HER2 Directed Therapy for Gastric/Esophageal Cancers

Opinion Statement The majority of patients with esophagogastric cancer present with advanced disease, which is incurable. Systemic chemotherapy can lead to a decrease in cancer-related symptoms and prolongs survival. However, even with treatment, the prognosis remains poor; most patients with advanc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Current treatment options in oncology Ročník 15; číslo 3; s. 395 - 404
Hlavní autoři: Won, Elizabeth, Janjigian, Yelena J., Ilson, David H.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Boston Springer US 01.09.2014
Springer Nature B.V
Témata:
Antibodies, Monoclonal, Humanized - pharmacology
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Diet
Drug Resistance, Neoplasm
Esophageal Neoplasms - diagnosis
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - etiology
Esophageal Neoplasms - metabolism
Humans
Life Style
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Oncology
Prognosis
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - metabolism
Section Editor
Stomach Neoplasms - diagnosis
Stomach Neoplasms - drug therapy
Stomach Neoplasms - etiology
Stomach Neoplasms - metabolism
Trastuzumab
Upper Gastrointestinal Cancers (L Rajdev
HER2 positive
Treatment
Gastroesophageal junction
Gastric cancer
Esophageal cancer
ISSN:1527-2729, 1534-6277, 1534-6277
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Opinion Statement The majority of patients with esophagogastric cancer present with advanced disease, which is incurable. Systemic chemotherapy can lead to a decrease in cancer-related symptoms and prolongs survival. However, even with treatment, the prognosis remains poor; most patients with advanced disease have a median overall survival less than one year. Molecularly targeted therapies, such as those targeting human epidermal growth factor receptor 2 (HER2), are anticipated to improve the current status of systemic treatment beyond conventional cytotoxic therapy. Trastuzumab in combination with chemotherapy in patients is the first molecular agent in metastatic HER2 positive gastric and gastroesophageal adenocarcinomas to result in improvements in response rates, time to progression and survival. Trastuzumab is now being investigated in the neoadjuvant and adjuvant setting. Unfortunately, as with breast cancer, many esophagogastric patients will develop resistance to trastuzumab. Several promising therapies are currently under investigation as monotherapy and in combination with chemotherapy in the first and second line setting.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1527-2729
1534-6277
1534-6277
DOI:10.1007/s11864-014-0292-6